In Brief: Franklin Ophthalmic Instruments
This article was originally published in The Gray Sheet
Executive Summary
Franklin Ophthalmic Instruments: Completes first phase of internal audit revealing "certain accounting irregularities which require further investigation to quantify." Conducted through a "special committee" of the company's board of directors, the ongoing investigation is seeking to determine whether "a restatement of previously disclosed financial information" is required. During the audit, Romeoville, Illinois-based Franklin is advising that current filings with the Securities and Exchange Commission "should not be relied upon" to evaluate the company or as a basis for investments...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.